{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:19:01Z","timestamp":1795105141268,"version":"4.10.3"},"reference-count":7,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>This post hoc analysis of 2 randomized clinical trials evaluates baseline and early treatment response factors associated with longer faricimab dosing intervals in patients with neovascular age-related macular degeneration.<\/jats:p>","DOI":"10.1001\/jamaophthalmol.2026.4385","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:32Z","timestamp":1792076432000},"page":"1063","source":"Crossref","is-referenced-by-count":0,"title":["Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"144","author":[{"given":"Colin S.","family":"Tan","sequence":"first","affiliation":[{"name":"Fundus Image Reading Center, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bakall","sequence":"additional","affiliation":[{"name":"Associated Retina Consultants, Phoenix, Arizona"},{"name":"University of Arizona College of Medicine, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Hock Chuan","family":"Koh","sequence":"additional","affiliation":[{"name":"Eye & Retina Surgeons, Camden Medical Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Vakharia","sequence":"additional","affiliation":[{"name":"Retina Vitreous Associates of Florida, Palm Harbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Sambhara","sequence":"additional","affiliation":[{"name":"Eye Clinic of Wisconsin, Wausau"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Maier","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum rechts der Isar, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quresh","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Margaron","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriji","family":"Patel","sequence":"additional","affiliation":[{"name":"Genentech, Inc, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Souied","sequence":"additional","affiliation":[{"name":"University Paris Est Creteil, Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"eld260015r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076","article-title":"TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration.","volume":"1","author":"Khanani","year":"2021","journal-title":"Ophthalmol Sci"},{"issue":"10326","key":"eld260015r2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"eld260015r3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2.","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"issue":"5","key":"eld260015r4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.oret.2026.02.001","article-title":"Potential 20-week faricimab dosing in wet age-related macular degeneration.","volume":"10","author":"Ambresin","year":"2026","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"eld260015r5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ophtha.2024.11.023","article-title":"Anatomic outcomes with faricimab vs aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration.","volume":"132","author":"Cheung","year":"2025","journal-title":"Ophthalmology"},{"issue":"7","key":"eld260015r6","first-page":"5690","article-title":"Greater reduction in pigment epithelial detachment size in TENAYA\/LUCERNE with faricimab 6.0 mg vs aflibercept 2.0 mg during head-to-head dosing in patients with nAMD.","volume":"65","author":"London","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"eld260015r7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1001\/jamaophthalmol.2025.6365","article-title":"Rapid fluid resolution and durability with faricimab in neovascular age-related macular degeneration.","volume":"144","author":"Pitcher","year":"2026","journal-title":"JAMA Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2854986\/jamaophthalmology_tan_2026_ld_260015_1794515917.52646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:00:29Z","timestamp":1795104029000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2854986"}},"subtitle":["A Post Hoc Analysis of the TENAYA and LUCERNE Trials"],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2026.4385","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11,1]]}}}